{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:34:59Z","timestamp":1789824899255,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services","award":["HHSB272201000021I"],"award-info":[{"award-number":["HHSB272201000021I"]}]},{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services","award":["HHSN272201100022I"],"award-info":[{"award-number":["HHSN272201100022I"]}]},{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services","award":["HHSN272201100016I"],"award-info":[{"award-number":["HHSN272201100016I"]}]},{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services","award":["R44AI100401"],"award-info":[{"award-number":["R44AI100401"]}]},{"name":"USC Dornsife College of Letters, Arts and Sciences"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.antiviral.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,3,3]],"date-time":"2018-03-03T07:12:50Z","timestamp":1520061170000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses"],"prefix":"10.1016","volume":"153","author":[{"given":"Karoly","family":"Toth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline F.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoling","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Tollefson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroll B.","family":"Hartline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglei","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris A.","family":"Kashemirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Harteg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Reyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5748-4750","authenticated-orcid":false,"given":"Elke","family":"Lipka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Prichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.M.","family":"Wold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.03.001_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/15257770.2015.1034363","article-title":"Synthesis and comparative study of anti-adenoviral activity of 6-azacytidine and its analogues","volume":"34","author":"Alexeeva","year":"2015","journal-title":"Nucleos. Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.03.001_bib2","series-title":"Fields Virology","first-page":"1704","article-title":"Adenoviridae","author":"Berk","year":"2013"},{"key":"10.1016\/j.antiviral.2018.03.001_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.001_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","article-title":"Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir","volume":"36","author":"Cundy","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2018.03.001_bib6","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2018.03.001_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/bmb\/ldt011","article-title":"Recent developments in anti-herpesvirus drugs","volume":"106","author":"Field","year":"2013","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.antiviral.2018.03.001_bib8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1586\/14787210.2014.948847","article-title":"Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses","volume":"12","author":"Florescu","year":"2014","journal-title":"Expert Rev. Anti Infective Ther."},{"key":"10.1016\/j.antiviral.2018.03.001_bib9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","article-title":"Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled Phase II trial","volume":"23","author":"Grimley","year":"2017","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.antiviral.2018.03.001_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01623-16","article-title":"Suppression of adenovirus replication by cardiotonic steroids","volume":"91","author":"Grosso","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.03.001_bib12","first-page":"99","article-title":"Synthesis and antiviral evalution of some novel pyrazoles and pyrazolo[3,4-d]pyridazines bearing 5,6,7,8-tetrahydronaphthalene","volume":"70","author":"Hamdy","year":"2013","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.antiviral.2018.03.001_bib13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.03.001_bib14","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2174\/1381612033453668","article-title":"Phosphonomethoxyalkyl analogs of nucleotides","volume":"9","author":"Holy","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.antiviral.2018.03.001_bib15","series-title":"Nucleic Acids Symp. Ser.","first-page":"33","article-title":"Stereospecific syntheses of 9-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA)","author":"Holy","year":"1987"},{"key":"10.1016\/j.antiviral.2018.03.001_bib16","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1135\/cccc19872775","article-title":"Synthesis of isomeric and enantiomeric O-phosphonylmethyl derivatives of 9-(2,3-dihydroxypropyl)adenine","volume":"52","author":"Holy","year":"1987","journal-title":"Collect. Czechoslov. Chem. Commun."},{"key":"10.1016\/j.antiviral.2018.03.001_bib17","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.001_bib18","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/v2102213","article-title":"Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate","volume":"2","author":"Hostetler","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.03.001_bib19","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/AAC.04534-14","article-title":"A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations","volume":"59","author":"Hutterer","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.001_bib20","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jpeds.2013.03.070","article-title":"22q11.2 deletion syndrome with life-threatening adenovirus infection","volume":"163","author":"Ip","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.antiviral.2018.03.001_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/505498","article-title":"Adenovirus infections in transplant recipients","volume":"43","author":"Ison","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.03.001_bib22","series-title":"Diagnostic Microbiology of the Immunocompromised Host","first-page":"217","article-title":"Adenovirus","author":"Ison","year":"2016"},{"key":"10.1016\/j.antiviral.2018.03.001_bib24","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1016\/j.bmcl.2016.09.071","article-title":"First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach","volume":"26","author":"Kang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.03.001_bib25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1515\/jcim-2016-0050","article-title":"Anti-adenovirus activity, antioxidant potential, and phenolic content of black tea (Camellia sinensis Kuntze) extract","volume":"13","author":"Karimi","year":"2016","journal-title":"J. Complement. Integr. Med."},{"key":"10.1016\/j.antiviral.2018.03.001_bib26","first-page":"796","article-title":"Cellular immune therapy for viral infections in transplant patients","volume":"138","author":"Khanna","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.antiviral.2018.03.001_bib27","doi-asserted-by":"crossref","first-page":"e0122642","DOI":"10.1371\/journal.pone.0122642","article-title":"Outcomes of early administration of cidofovir in non-immunocompromised patients with severe adenovirus pneumonia","volume":"10","author":"Kim","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.03.001_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2012.03.011","article-title":"Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery","volume":"94","author":"Kneidinger","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.001_bib29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.03.001_bib30","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/v2122740","article-title":"Development of CMX001 for the treatment of poxvirus infections","volume":"2","author":"Lanier","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.03.001_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/0885066616681272","article-title":"Treatment of adenoviral acute respiratory distress syndrome using cidofovir with extracorporeal membrane oxygenation","volume":"32","author":"Lee","year":"2017","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.antiviral.2018.03.001_bib32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/rmv.589","article-title":"Clinical features and treatment of adenovirus infections","volume":"18","author":"Lenaerts","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.03.001_bib33","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1182\/blood-2010-04-259291","article-title":"How I treat adenovirus in hematopoietic stem cell transplant recipients","volume":"116","author":"Lindemans","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2018.03.001_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.03.001_bib35","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/leu.2010.4","article-title":"Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation","volume":"24","author":"Lion","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.antiviral.2018.03.001_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virusres.2012.12.001","article-title":"Dioscin's antiviral effect in vitro","volume":"172","author":"Liu","year":"2013","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.03.001_bib37","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.drudis.2015.07.007","article-title":"Antiadenovirus drug discovery: potential targets and evaluation methodologies","volume":"20","author":"Martinez-Aguado","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2018.03.001_bib38","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1586\/14787210.2013.836964","article-title":"Diagnosis and treatment of adenovirus infection in immunocompromised patients","volume":"11","author":"Matthes-Martin","year":"2013","journal-title":"Expert Rev. Anti-Infective Ther."},{"key":"10.1016\/j.antiviral.2018.03.001_bib39","unstructured":"McKenna, C.E., Kashemirov, B.A., Krylov, I.S., Zakharova, V.M. Method to improve antiviral activity of nucleotide analogue drugs, US Patent 9,550,803 B2, Jan. 24, 2017."},{"key":"10.1016\/j.antiviral.2018.03.001_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ardp.201400387","article-title":"Novel antiviral compounds against gastroenteric viral infections","volume":"348","author":"Mohamed","year":"2015","journal-title":"Arch. Pharm. Weinh."},{"key":"10.1016\/j.antiviral.2018.03.001_bib41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/135965350501000204","article-title":"In vitro susceptibility of adenovirus to antiviral drugs is species-dependent","volume":"10","author":"Morfin","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.03.001_bib42","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections","volume":"51","author":"O'Reilly","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.antiviral.2018.03.001_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcv.2010.10.016","article-title":"Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001","volume":"50","author":"Paolino","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.03.001_bib45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.antiviral.2015.05.010","article-title":"Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir","volume":"120","author":"Pozzuto","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.001_bib46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virusres.2010.11.004","article-title":"The search for new therapies for human cytomegalovirus infections","volume":"157","author":"Prichard","year":"2011","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.03.001_bib47","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1128\/AAC.00429-13","article-title":"Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses","volume":"57","author":"Prichard","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.001_bib48","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11908-014-0416-y","article-title":"Adenovirus: current epidemiology and emerging approaches to prevention and treatment","volume":"16","author":"Sandkovsky","year":"2014","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.antiviral.2018.03.001_bib49","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3851\/IMP3047","article-title":"Biological antivirals for treatment of adenovirus infections","volume":"21","author":"Schaar","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.03.001_bib50","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1124\/mol.53.2.270","article-title":"Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs","volume":"53","author":"Sjoberg","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.03.001_bib52","first-page":"223","article-title":"Preparation and titration of CsCl-banded adenovirus stocks","volume":"130","author":"Tollefson","year":"2007","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.antiviral.2018.03.001_bib53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2014.10.005","article-title":"Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model","volume":"112","author":"Tollefson","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.001_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00284-17","article-title":"Pathology in permissive Syrian hamsters after infection with species C human adenovirus (HAdV-C) is the result of virus replication: HAdV-C6 replicates more and causes more pathology than HAdV-C5","volume":"91","author":"Tollefson","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.03.001_bib55","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.0800200105","article-title":"Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model","volume":"105","author":"Toth","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.03.001_bib56","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/v7031409","article-title":"Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters","volume":"7","author":"Toth","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.03.001_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-398342-8.00003-3","article-title":"Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds","volume":"115","author":"Wold","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.antiviral.2018.03.001_bib58","series-title":"Fields Virology","first-page":"1732","article-title":"Adenoviruses","author":"Wold","year":"2013"},{"key":"10.1016\/j.antiviral.2018.03.001_bib59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virol.2017.10.015","article-title":"Male Syrian hamsters are more susceptible to intravenous infection with species C human adenoviruses than are females","volume":"514","author":"Ying","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.03.001_bib60","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1128\/AAC.03860-14","article-title":"Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters","volume":"58","author":"Ying","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.001_bib61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.virol.2015.07.024","article-title":"Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters","volume":"485","author":"Ying","year":"2015","journal-title":"Virology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217308367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217308367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T05:11:44Z","timestamp":1660540304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217308367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":56,"alternative-id":["S0166354217308367"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.03.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}